What is Parry Romberg Syndrome?
Parry Romberg Syndrome, commonly known as Romberg syndrome or progressive facial hemiatrophy, is a disease in which one side of the face's tissue gradually deteriorates. The soft tissue (muscle and fat) decreases over time, the facial bones may alter, and the skin may thin. The degree of this atrophy varies greatly from patient to patient, and can range from moderate to severe. One in every 250,000 persons is estimated to be affected with Parry-Romberg syndrome, which qualifies it to be called as a rare disease. Few of the symptoms of Parry-Romberg syndrome include seizures a severe headaches. Although many times doctors misdiagnose Parry-Romberg syndrome as linear scleroderma, which may lead to further side effects because of improper medication. Women are said to be more affected than men with 3:2 ration prevalent. Growing number of Parry-Romberg syndrome patients worldwide as well as emergence of other skin and neurological abnormalities has led to the growth of the Parry-Romberg syndrome market. North America and Asia Pacific are the two fastest growing markets of parry romberg syndrome.
The market study is broken down and major geographies with country level break-up.
Growing number of rare diseases as well as prevalence of rare skin disorders and neurological abnormalities has propagated increased investments in the research and development of modern medicine and biotech studies. Emergence of new drug delivery systems and use of artificial intelligence in drug discovery will significantly accelerate the growth in the parry romberg syndrome’s market. North America is the largest market of Parry-Romberg syndrome. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.
Johnson & Johnson Services, Inc. (United States), Sanofi S.A. (France), Pfizer, Inc. (United States), AstraZeneca plc (United Kingdom), Medtronic plc (Ireland), GlaxoSmithKline (United Kingdom), Abbott Laboratories (United States), Biogen, Inc. (United States) and DePuy Synthes (United States) are some of the key players that are part of study coverage.
AdvanceMarketAnalytics has segmented the market of Global Parry Romberg Syndrome market by Type, Application and Region.
On the basis of geography, the market of Parry Romberg Syndrome has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End Use, the sub-segment i.e. Hospital will boost the Parry Romberg Syndrome market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Dignosis, the sub-segment i.e. Physical Examination will boost the Parry Romberg Syndrome market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment Type, the sub-segment i.e. Drug Treatment will boost the Parry Romberg Syndrome market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Gender, the sub-segment i.e. Male will boost the Parry Romberg Syndrome market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Surgery is required in Significant Number of Cases
- Growing Prevalence of Rare Diseases
- Recent Covid 19 Pandemic has led to Increased Investments in Biotechnology Infrastructure and Institutions
- Increasing Number of Patients suffering from Neurological Abnormalities and Skin Diseases
- The Parry Romberg Syndrome is found to be more Prevalent in Women than Men, presenting an Opportunity to Innovate Drugs Specifically for Each Gender
- Parry Romberg Syndrome may be misdiagnosed as Linear Scleroderma
- The Medical Study of Parry Romberg Syndrome is still in its Early Stages
Key Target AudienceParry Romberg Syndrome Treatment Providers, New Entrants/Investors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industries
About ApproachTo evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand companys positioning regarding market value, volume and their market share for regional as well as global.
Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.
Frequently Asked Questions (FAQ):
1. What all players are profiled in the study?
The standard version of the report profiles players such as Johnson & Johnson Services, Inc. (United States), Sanofi S.A. (France), Pfizer, Inc. (United States), AstraZeneca plc (United Kingdom), Medtronic plc (Ireland), GlaxoSmithKline (United Kingdom), Abbott Laboratories (United States), Biogen, Inc. (United States) and DePuy Synthes (United States) etc.
2. Can we have customized study for Parry Romberg Syndrome Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
3. What would be the Market Size of Parry Romberg Syndrome Market by 2026?
Analysts at AMA estimates Parry Romberg Syndrome Market to reach USD Million by 2026.